# Study to Evaluate the Safety and Pharmacokinetics of CKD-379

> **NCT05952219** · PHASE1 · UNKNOWN · sponsor: **Chong Kun Dang Pharmaceutical** · enrollment: 32 (actual)

## Conditions studied

- Type II Diabetes Mellitus

## Interventions

- **DRUG:** CKD-379
- **DRUG:** D759+D745+D029+D150

## Key facts

- **NCT ID:** NCT05952219
- **Lead sponsor:** Chong Kun Dang Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-06-02
- **Primary completion:** 2023-06-19
- **Final completion:** 2023-10-30
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2023-07-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05952219

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05952219, "Study to Evaluate the Safety and Pharmacokinetics of CKD-379". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT05952219. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*